

Christopher C Rowe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9053112/publications.pdf>

Version: 2024-02-01

254
papers

38,635
citations

11608

70
h-index

3021

188
g-index

336
all docs

336
docs citations

336
times ranked

26268
citing authors

#	ARTICLE	IF	CITATIONS
1	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
2	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.4	5,550
3	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014, 13, 614-629.	4.9	2,657
4	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , 2013, 12, 357-367.	4.9	1,738
5	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
6	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056.	18.1	1,210
7	High performance plasma amyloid- β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018, 554, 249-254.	13.7	1,180
8	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
9	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	1.5	885
10	β -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844.	3.7	739
11	Longitudinal assessment of β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	2.8	730
12	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 672-687.	0.6	661
13	Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <i>Lancet Neurology</i> , 2008, 7, 129-135.	4.9	631
14	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.4	603
15	Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2013, 9, e-1-16.	0.4	443
16	Tau imaging: early progress and future directions. <i>Lancet Neurology</i> , 2015, 14, 114-124.	4.9	432
17	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. <i>Alzheimer's and Dementia</i> , 2015, 11, 964-974.	0.4	400
18	Relationship between atrophy and β -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	2.8	322

#	ARTICLE	IF	CITATIONS
19	Imaging tau and amyloid- β^2 proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
20	Amyloid Imaging with ¹⁸ F-Florbetaben in Alzheimer Disease and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1210-1217.	2.8	311
21	¹⁸ F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. <i>Brain</i> , 2011, 134, 1089-1100.	3.7	299
22	Subtypes of progressive aphasia: application of the international consensus criteria and validation using β^2 -amyloid imaging. <i>Brain</i> , 2011, 134, 3030-3043.	3.7	294
23	Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Journal of Nuclear Medicine</i> , 2013, 54, 476-490.	2.8	248
24	Brain Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1733-1740.	2.8	226
25	Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2018, 141, 888-902.	3.7	226
26	Regional dynamics of amyloid- β^2 deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012, 135, 2126-2139.	3.7	222
27	Visual Assessment Versus Quantitative Assessment of ¹¹ C-PIB PET and ¹⁸ F-FDG PET for Detection of Alzheimer's Disease. <i>Journal of Nuclear Medicine</i> , 2007, 48, 547-552.	2.8	220
28	Cerebral quantitative susceptibility mapping predicts amyloid- β^2 -related cognitive decline. <i>Brain</i> , 2017, 140, 2112-2119.	3.7	213
29	Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.	1.5	204
30	Predicting Alzheimer disease with β^2 -amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013, 74, 905-913.	2.8	194
31	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	3.7	182
32	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. <i>Frontiers in Neurology</i> , 2014, 4, 205.	1.1	176
33	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	4.9	175
34	Sex, amyloid, and <i>APOE</i> ϵ^4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.4	169
35	Comparison of ¹¹ C-PiB and ¹⁸ F-florbetaben for β^2 imaging in ageing and Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 983-989.	3.3	161
36	Amyloid- β^2 , Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	6.0	160

#	ARTICLE	IF	CITATIONS
37	High Striatal Amyloid \hat{I}^2 -Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. <i>Archives of Neurology</i> , 2009, 66, 1537-44.	4.9	156
38	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 816-826.	3.3	156
39	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PiB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.4	155
40	<i>In Vitro</i> Characterization of Pittsburgh Compound-B Binding to Lewy Bodies. <i>Journal of Neuroscience</i> , 2007, 27, 10365-10371.	1.7	154
41	Head-to-Head Comparison of ¹¹ C-PiB and ¹⁸ F-AZD4694 (NAV4694) for \hat{I}^2 -Amyloid Imaging in Aging and Dementia. <i>Journal of Nuclear Medicine</i> , 2013, 54, 880-886.	2.8	145
42	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	0.7	139
43	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.4	135
44	Association of Cerebral Amyloid- \hat{I}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
45	Independent contribution of temporal \hat{I}^2 -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	3.7	132
46	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	3.7	130
47	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.5	125
48	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016, 39, 1063-1068.	0.6	123
49	Biochemically-defined pools of amyloid- \hat{I}^2 in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017, 140, 1486-1498.	3.7	123
50	Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015, 3, 13-26.	1.1	120
51	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	0.8	111
52	BDNF Val66Met, \hat{A}^2 amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	1.5	109
53	Implementation and Validation of an Adaptive Template Registration Method for ¹⁸ F-Flutemetamol Imaging Data. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1472-1478.	2.8	101
54	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. <i>Alzheimer's and Dementia</i> , 2018, 14, 1565-1571.	0.4	98

#	ARTICLE	IF	CITATIONS
55	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
56	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.5	96
57	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	1.5	96
58	A β -amyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 75-88.	2.5	96
59	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
60	Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2009, 50, 198-204.	2.8	95
61	The ART of Loss: A β Imaging in the Evaluation of Alzheimer's Disease and other Dementias. <i>Molecular Neurobiology</i> , 2008, 38, 1-15.	1.9	94
62	Implementing the centiloid transformation for 11C-PiB and A β -amyloid 18F-PET tracers using CapAIBL. <i>NeuroImage</i> , 2018, 183, 387-393.	2.1	94
63	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain A β -amyloid burden. <i>Translational Psychiatry</i> , 2018, 8, 47.	2.4	92
64	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.3	90
65	Basal forebrain atrophy correlates with amyloid A β burden in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 105-113.	1.4	89
66	18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2053-2059.	3.3	87
67	Standardized Expression of ¹⁸ F-NAV4694 and ¹¹ C-PiB A β -Amyloid PET Results with the Centiloid Scale. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1233-1237.	2.8	80
68	A β imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 431-436.	0.9	78
69	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	1.2	76
70	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 5698.	5.8	76
71	Radiation Dosimetry of A β -Amyloid Tracers ¹¹ C-PiB and ¹⁸ F-BAY94-9172. <i>Journal of Nuclear Medicine</i> , 2009, 50, 309-315.	2.8	75
72	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	1.1	75

#	ARTICLE	IF	CITATIONS
73	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	1.5	75
74	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	3.0	74
75	Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B. <i>Archives of Neurology</i> , 2007, 64, 1140.	4.9	72
76	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 19-26.	1.2	72
77	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Neurobiology of Aging</i> , 2015, 36, 1231-1238.	1.5	71
78	Association of β -Amyloid and Apolipoprotein E ϵ 4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 488.	4.5	70
79	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 11.	3.0	68
80	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014, 15, S11.	1.2	67
81	β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 743.	0.4	66
82	Amyloid- β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 677-686.	1.2	63
83	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017, 7, 9766.	1.6	59
84	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 622-635.	1.8	59
85	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
86	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
87	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.5	58
88	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
89	β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	3.3	55
90	Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. <i>EJNMMI Research</i> , 2018, 8, 107.	1.1	55

#	ARTICLE	IF	CITATIONS
91	In vitro characterization of [¹⁸ F]-florbetaben, an Aβ ² imaging radiotracer. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1042-1048.	0.3	54
92	Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis. <i>Medical Clinics of North America</i> , 2013, 97, 377-398.	1.1	52
93	Aβ ² amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013, 9, 538-545.	0.4	51
94	Comparison of ¹⁸ F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816.	0.4	50
95	¹⁸ F-florbetaben Aβ ² imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 4.	3.0	49
96	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 455-463.	1.3	49
97	Optimal Reference Region to Measure Longitudinal Amyloid-β ² Change with ¹⁸ F-Florbetaben PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1300-1306.	2.8	49
98	Clinical Profile of PiB-Positive Corticobasal Syndrome. <i>PLoS ONE</i> , 2013, 8, e61025.	1.1	48
99	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β ² Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	1.2	47
100	Subjective Memory Complaints in APOE ε ₄ Carriers are Associated with High Amyloid-β ² Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	1.2	45
101	Relationship between Memory Performance and β ² -Amyloid Deposition at Different Stages of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2012, 10, 141-144.	0.8	43
102	MR-Less Surface-Based Amyloid Assessment Based on ¹¹ C PiB PET. <i>PLoS ONE</i> , 2014, 9, e84777.	1.1	43
103	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.0	43
104	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015, 11, 850-859.	0.4	43
105	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-β ² . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	1.2	42
106	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.4	42
107	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and Aβ Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.3	40
108	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012, 24, 197-204.	0.6	39

#	ARTICLE	IF	CITATIONS
109	Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	1.2	38
110	Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials. <i>PLoS ONE</i> , 2013, 8, e58816.	1.1	38
111	Differential Diagnosis in Alzheimer's Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. <i>Neurodegenerative Diseases</i> , 2012, 10, 161-165.	0.8	37
112	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	0.6	37
113	$A\beta$ -related memory decline in <i>APOE</i> ϵ 4 noncarriers. <i>Neurology</i> , 2016, 86, 1635-1642.	1.5	37
114	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 354-361.	1.1	37
115	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. <i>Computerized Medical Imaging and Graphics</i> , 2015, 46, 269-276.	3.5	35
116	Effect of <i>APOE</i> Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1293-1302.	1.2	35
117	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	1.2	35
118	Episodic Memory Decline Predicts Cortical Amyloid Status in Community-Dwelling Older Adults. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 627-637.	1.2	34
119	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- β : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	1.2	34
120	Association of β -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.5	34
121	Cognitive consequences of high $A\beta$ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.0	33
122	Positron Emission Tomographic Imaging in Stroke. <i>Stroke</i> , 2016, 47, 113-119.	1.0	33
123	Amyloid Imaging in Alzheimer's Disease and Other Dementias. <i>Brain Imaging and Behavior</i> , 2009, 3, 246-261.	1.1	32
124	Impact of <i>APOE</i> - ϵ 4 carriage on the onset and rates of neocortical $A\beta$ -amyloid deposition. <i>Neurobiology of Aging</i> , 2020, 95, 46-55.	1.5	32
125	Prediction of Amyloid- β Pathology in Amnesic Mild Cognitive Impairment with Neuropsychological Tests. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 451-462.	1.2	31
126	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in <i>APOE</i> ϵ 4-positive cognitively normal adults with high $A\beta$ -amyloid burden. <i>Scientific Reports</i> , 2018, 8, 2034.	1.6	31

#	ARTICLE	IF	CITATIONS
127	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 241-252.	2.5	30
128	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2225-2232.	3.3	30
129	Concordance of Text Message Ecological Momentary Assessment and Retrospective Survey Data Among Substance-Using Men Who Have Sex With Men: A Secondary Analysis of a Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2016, 4, e44.	1.8	30
130	Amyloid imaging. <i>International Psychogeriatrics</i> , 2011, 23, S41-S49.	0.6	29
131	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014, 204, 400-401.	1.7	29
132	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	0.6	29
133	Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 611-617.	1.2	29
134	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
135	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1299-1305.	1.2	28
136	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	2.0	27
137	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1193-1211.	1.2	27
138	Plasma Amyloid- β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1057-1065.	1.2	27
139	Predicting Alzheimer disease from a blood-based biomarker profile. <i>Neurology</i> , 2016, 87, 1093-1101.	1.5	26
140	Early detection of amyloid load using 18F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 67.	3.0	26
141	Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 21-30.	0.9	25
142	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , 2019, 85, 241-250.	2.8	25
143	Automated 11C-PiB Standardized Uptake Value Ratio. <i>Academic Radiology</i> , 2008, 15, 1376-1389.	1.3	24
144	The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	0.6	24

#	ARTICLE	IF	CITATIONS
145	¹⁸ F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1547-1553.	2.8	24
146	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010, 5, 33-53.	1.5	23
147	A "Disease Severity Index"™ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017, 7, 44368.	1.6	23
148	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017, 13, 388-398.	0.4	23
149	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β -Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 585-598.	0.3	23
150	Klotho allele status is not associated with $A\beta$ and APOE $\epsilon 4$ -related cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 162-165.	1.5	23
151	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 303-315.	1.2	23
152	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	1.5	23
153	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI β updates and global perspectives. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12226.	1.8	23
154	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE $\epsilon 4$ and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	1.1	22
155	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 16.	3.0	22
156	Long Night's Journey into the Day: Amyloid- β Imaging in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S349-S359.	1.2	21
157	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform. , 2014, , .		21
158	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017, 29, 1825-1834.	0.6	21
159	Rates of age- and amyloid β -associated cortical atrophy in older adults with superior memory performance. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 566-575.	1.2	21
160	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	1.2	21
161	Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. <i>Brain Communications</i> , 2020, 2, fcaa041.	1.5	21
162	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	2.8	21

#	ARTICLE	IF	CITATIONS
163	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
164	Amyloid β associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	1.2	19
165	Relationship Between Amyloid- β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	1.2	19
166	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. NeuroImage: Clinical, 2020, 28, 102479.	1.4	19
167	Plasma transferrin and hemopexin are associated with altered $A\beta$ uptake and cognitive decline in Alzheimer's disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	3.0	19
168	Advances in molecular imaging for the diagnosis of dementia. Expert Opinion on Medical Diagnostics, 2009, 3, 705-716.	1.6	18
169	The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants "at risk" for dementia. International Review of Psychiatry, 2013, 25, 726-737.	1.4	18
170	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. Journal of Neuroscience Methods, 2012, 205, 96-109.	1.3	17
171	Management Impact of FDG-PET in Dementia: Results from a Tertiary Center Memory Clinic. Journal of Alzheimer's Disease, 2014, 42, 885-892.	1.2	17
172	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	1.7	16
173	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	3.3	16
174	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
175	<i>APOE</i> β resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.4	16
176	¹¹ C-PiB PET ABri Imaging in Worster-Drought Syndrome (Familial British Dementia): A Case Report. Journal of Alzheimer's Disease, 2010, 19, 423-428.	1.2	15
177	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 977-988.	1.2	15
178	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. Scientific Reports, 2019, 9, 17069.	1.6	15
179	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. NeuroImage, 2021, 226, 117593.	2.1	15
180	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	1.1	14

#	ARTICLE	IF	CITATIONS
181	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 170-179.	1.5	14
182	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12307.	1.2	14
183	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018, 7-8, 14-20.	0.1	13
184	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018, 70, 22-29.	1.6	13
185	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 193-201.	1.2	12
186	Mesial temporal tau in amyloid- β -negative cognitively normal older persons. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 51.	3.0	12
187	β -Amyloid and Tau Imaging in Chronic Traumatic Brain Injury. <i>Neurology</i> , 2022, 99, .	1.5	12
188	Tau imaging with PET: an overview of challenges, current progress, and future applications. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 405-413.	0.4	11
189	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 551-561.	1.2	10
190	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	0.6	9
191	APOE ϵ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 411-422.	1.2	9
192	A head-to-head comparison of cerebral blood flow SPECT and 18 F- β FDG PET in the diagnosis of Alzheimer's Disease. <i>Internal Medicine Journal</i> , 2020, 51, 1243-1250.	0.5	8
193	PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study. <i>Psychiatry Research - Neuroimaging</i> , 2021, 316, 111354.	0.9	8
194	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 771214.	1.7	8
195	Amyloid- β , Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 163-173.	1.2	7
196	The Interaction Between Vascular Risk Factors, Cerebral Small Vessel Disease, and Amyloid Burden in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1617-1628.	1.2	7
197	The heritability of amyloid burden in older adults: the Older Australian Twins Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 303-308.	0.9	7
198	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	7

#	ARTICLE	IF	CITATIONS
199	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. Lecture Notes in Computer Science, 2016, , 109-116.	1.0	6
200	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. BMJ Open, 2020, 10, e038312.	0.8	6
201	Human biodistribution and internal dosimetry of 4-[¹⁸ F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart. EJNMMI Research, 2020, 10, 61.	1.1	6
202	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's disease. Neuroscience Letters, 2020, 731, 135078.	1.0	6
203	Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study. Supportive Care in Cancer, 0, , .	1.0	6
204	Advances in structural and molecular neuroimaging in Alzheimer's disease. Medical Journal of Australia, 2011, 194, S20-3.	0.8	5
205	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation. , 2011, , .		5
206	Automatic detection of small spherical lesions using multiscale approach in 3D medical images. , 2013, , .		5
207	Imago Mundi, Imago AD, Imago ADNI. Alzheimer's Research and Therapy, 2014, 6, 62.	3.0	5
208	COMT val158met is not associated with A β -amyloid and APOE ϵ 4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
209	SPON1 Is Associated with Amyloid- β and APOE ϵ 4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	1.2	5
210	Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study. Neuropsychological Rehabilitation, 2022, 32, 1530-1549.	1.0	5
211	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.4	5
212	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study.. Psychological Assessment, 2018, 30, 1308-1316.	1.2	5
213	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A β 242 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	1.5	5
214	Brain age in chronic traumatic brain injury. NeuroImage: Clinical, 2022, 35, 103039.	1.4	5
215	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid- β . Neurobiology of Disease, 2022, 171, 105783.	2.1	5
216	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	1.8	5

#	ARTICLE	IF	CITATIONS
217	IC-O3-01: The Centiloid Scale: Standardization of amyloid imaging measures. , 2013, 9, P8-P8.		4
218	Untangling tau imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 39-42.	1.2	4
219	Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. Brain, 2018, 141, e45-e45.	3.7	4
220	Self-reported confusion is related to global and regional β -amyloid: data from the Women's healthy ageing project. Brain Imaging and Behavior, 2018, 12, 78-86.	1.1	4
221	Quantitative Approaches to Amyloid Imaging. Methods in Molecular Biology, 2011, 680, 201-225.	0.4	4
222	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	1.2	4
223	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in β - and β + Older Adults. Neurology, 2022, 98, e1704-e1715.	1.5	4
224	O2-08-02: The Tau Meter Scale for the Generation of Continuous and Categorical Measures of Tau Deposits in the Brain: Results from β -AV1451 and β -THK5351 Tau Imaging Studies. Alzheimer's and Dementia, 2016, 12, P244.	0.4	3
225	Divergent Network Patterns of Amyloid- β Deposition in Logopenic and Amnesic Alzheimer's Disease Presentations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 24-31.	1.1	3
226	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.2	3
227	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	1.0	2
228	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 1039-1052.	1.2	2
229	β Imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. , 2014, , 213-254.		2
230	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies. Australian and New Zealand Journal of Psychiatry, 2023, 57, 594-602.	1.3	2
231	Alzheimer's disease detection using β -C-PiB with improved partial volume effect correction. Proceedings of SPIE, 2009, , .	0.8	1
232	O1-01-04: β accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study. , 2015, 11, P125-P125.		1
233	Relationship between amyloid and tau levels and its impact on tau spreading. Alzheimer's and Dementia, 2021, 17, .	0.4	1
234	β -MK6240 longitudinal tau PET in ageing and Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
235	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicines</i> , 2022, 10, 1045.	1.4	1
236	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0
237	O4-07-01: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL). , 2013, 9, P695-P695.		0
238	O3-07-01: AMYLOID β -RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS. , 2014, 10, P221-P221.		0
239	P1-145: Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB. , 2015, 11, P398-P398.		0
240	[S2â€“01â€“02]: COMPARISON OF DIFFERENT TAU PET TRACERS AND THEIR RELATIONSHIP TO AMYLOID. <i>Alzheimer's and Dementia</i> , 2017, 13, P541.	0.4	0
241	[P2â€“389]: LONGITUDINAL ASSESSMENT OF $A\beta$ ACCUMULATION WITH FLUTEMETAMOL. <i>Alzheimer's and Dementia</i> , 2017, 13, P778.	0.4	0
242	P2â€“364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [$F\alpha$ 18]â€“MK6240, A SECOND GENERATION SELECTIVE TAU TRACER. <i>Alzheimer's and Dementia</i> , 2018, 14, P831.	0.4	0
243	O2â€“06â€“05: CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P634.	0.4	0
244	Quantitative thresholds for 18 Fâ€“florbetaben PET for the detection of low amyloid load. <i>Alzheimer's and Dementia</i> , 2020, 16, e042933.	0.4	0
245	One year tau progression measured with Fâ€“18 MK6240 PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e044987.	0.4	0
246	Basal forebrain atrophy and tau pathology are correlated in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046111.	0.4	0
247	$A\beta$ Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
248	Differential associations of modifiable and nonâ€“modifiable dementia risk factors with memory decline and hippocampal volume loss in $A\beta$ and $A\beta$ + cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
249	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
250	Discordant low amyloidâ€“PET and high neocortical tau PET retention. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
251	Examining the structural correlates of amyloidâ€“beta in people with DLB. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
252	Unpacking cognitive composites: A longitudinal analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
253	Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
254	Plasma p217+tau concordance with ^{18F} NAV4694 beta-amyloid and ^{18F} MK6240 tau PET in mild Alzheimer's disease and cognitively unimpaired participants in the AIBL/ADNeT cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0